491 related articles for article (PubMed ID: 7693435)
21. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
[TBL] [Abstract][Full Text] [Related]
22. Didanosine: an updated review of its use in HIV infection.
Perry CM; Noble S
Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
[TBL] [Abstract][Full Text] [Related]
23. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
Krown SE; Aeppli D; Balfour HH
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
[TBL] [Abstract][Full Text] [Related]
24. Current and future trials with zidovudine.
Yeo JM
J Infect; 1989 Jan; 18 Suppl 1():93-6. PubMed ID: 2644366
[TBL] [Abstract][Full Text] [Related]
25. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
Adkins JC; Peters DH; Faulds D
Drugs; 1997 Jun; 53(6):1054-80. PubMed ID: 9179531
[TBL] [Abstract][Full Text] [Related]
26. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
[TBL] [Abstract][Full Text] [Related]
27. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
Husson RN; Shirasaka T; Butler KM; Pizzo PA; Mitsuya H
J Pediatr; 1993 Jul; 123(1):9-16. PubMed ID: 8391570
[TBL] [Abstract][Full Text] [Related]
28. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
Katzenstein DA; Hammer SM; Hughes MD; Gundacker H; Jackson JB; Fiscus S; Rasheed S; Elbeik T; Reichman R; Japour A; Merigan TC; Hirsch MS
N Engl J Med; 1996 Oct; 335(15):1091-8. PubMed ID: 8813039
[TBL] [Abstract][Full Text] [Related]
29. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Langtry HD; Campoli-Richards DM
Drugs; 1989 Apr; 37(4):408-50. PubMed ID: 2661194
[TBL] [Abstract][Full Text] [Related]
30. Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma.
Fischl MA
Am J Med; 1991 Apr; 90(4A):2S-7S. PubMed ID: 2018047
[TBL] [Abstract][Full Text] [Related]
31. Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS).
Kovacs JA; Deyton L; Davey R; Falloon J; Zunich K; Lee D; Metcalf JA; Bigley JW; Sawyer LA; Zoon KC
Ann Intern Med; 1989 Aug; 111(4):280-7. PubMed ID: 2757312
[TBL] [Abstract][Full Text] [Related]
32. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
Abrams DI; Goldman AI; Launer C; Korvick JA; Neaton JD; Crane LR; Grodesky M; Wakefield S; Muth K; Kornegay S
N Engl J Med; 1994 Mar; 330(10):657-62. PubMed ID: 7906384
[TBL] [Abstract][Full Text] [Related]
33. Zidovudine for treating AIDS. What physicians need to know.
Amin NM
Postgrad Med; 1989 Jul; 86(1):195-6, 201-8. PubMed ID: 2662155
[TBL] [Abstract][Full Text] [Related]
34. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Barry M; Gibbons S; Back D; Mulcahy F
Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
[TBL] [Abstract][Full Text] [Related]
35. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).
Whittington R; Brogden RN
Drugs; 1992 Oct; 44(4):656-83. PubMed ID: 1281077
[TBL] [Abstract][Full Text] [Related]
36. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Schooley RT; Ramirez-Ronda C; Lange JM; Cooper DA; Lavelle J; Lefkowitz L; Moore M; Larder BA; St Clair M; Mulder JW; McKinnis R; Pennington KN; Harrigan PR; Kinghorn I; Steel H; Rooney JF
J Infect Dis; 1996 Jun; 173(6):1354-66. PubMed ID: 8648207
[TBL] [Abstract][Full Text] [Related]
37. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
Fischl MA; Stanley K; Collier AC; Arduino JM; Stein DS; Feinberg JE; Allan JD; Goldsmith JC; Powderly WG
Ann Intern Med; 1995 Jan; 122(1):24-32. PubMed ID: 7985892
[TBL] [Abstract][Full Text] [Related]
38. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
[TBL] [Abstract][Full Text] [Related]
39. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
Kahn JO; Lagakos SW; Richman DD; Cross A; Pettinelli C; Liou SH; Brown M; Volberding PA; Crumpacker CS; Beall G
N Engl J Med; 1992 Aug; 327(9):581-7. PubMed ID: 1353607
[TBL] [Abstract][Full Text] [Related]
40. Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.
Langtry HD; Palmer KJ; Benfield P
Pharmacoeconomics; 1993 Apr; 3(4):309-37. PubMed ID: 10146993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
